Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

ARS Pharmaceuticals Q3 2026 Results: Net Loss of $35.6M, Loss Narrows

ARS Pharmaceuticals is focused on the commercialization of neffy, its intranasal epinephrine product, following recent regulatory approvals. The company reported 100,528,400 shares of common stock outstanding as of November 3, 2026, and is classified as a non-accelerated filer and smaller reporting company.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue37.732.5
Net income-35.6-51.2
EPS (diluted, $ a share)$-0.36$-0.52

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+16.0%
Operating margin-90.6%
Source

10-Q filed with the SEC, NASDAQ: SPRY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

ARS Pharmaceuticals, Inc.: key numbers

Share price
$3.59Close, Nov 16
Market cap
$361M
Shares outstanding
100.53MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from ARS Pharmaceuticals, Inc.

All →
4:04 PM ET 8-K
Financial Results

ARS Pharmaceuticals Financial Results

ARS Pharmaceuticals reported Q3 2026 financial results with total revenue of $37.7 million, driven by $33.4 million in U.S. net product revenue for neffy. The company achieved a 5% overall U.S. market share for neffy and reaffirmed its path to cash flow breakeven by year-end 2027.

Term
Q3 2026

“In August, we committed to three corporate priorities – steady market share gains with neffy, greater financial discipline with a path to cash flow breakeven by year-end 2027, and expansion of our needle-free epinephrine platform beyond anaphylaxis. I’m proud to report that our team has delivered on each.”

Donn Casale, President and Chief Executive Officer

“neffy is a highly differentiated product in a large market with genuine demand, and I am confident it can become the standard of care in the epinephrine market.”

Meg Smith, Chief Commercial Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.